# Huntington Disease

Confirm Huntington disease with targeted HTT CAG-repeat testing in the appropriate clinical context, distinguish phenocopies and secondary chorea, deliver structured predictive counseling, and target chorea, psychiatric disease, function, nutrition, and family planning through multidisciplinary care.

**Clinical question:** How should clinicians confirm, counsel, and manage Huntington disease across motor, psychiatric, cognitive, and family-planning decisions?

Updated: 2026-08-24T17:53:49.703570+00:00

## What matters in practice
- Use HTT CAG-repeat testing to confirm suspected Huntington disease in a patient with a compatible progressive motor syndrome; expansions of 36 or more repeats are disease-causing, while longer repeats are associated with earlier onset. [16]
- Do not approach predictive testing as a routine laboratory order: premanifest testing should be performed through a multidisciplinary process for an at-risk adult who elects to know mutation status. [16][19]
- Treat chorea when it impairs function or creates injury risk; tetrabenazine and deutetrabenazine are FDA-approved options, but tetrabenazine carries serious depression and suicidality warnings. [1][4][24]
- Chorea control is only one component of care; psychiatric symptoms, cognition, dysphagia, nutritional status, mobility, communication, caregiver needs, and reproductive decisions require longitudinal multidisciplinary management. [1][6][13]

## Confirm the phenotype before ordering HTT testing

A genetic result must be interpreted alongside the clinical syndrome and the testing indication.

In a symptomatic patient, obtain a three-generation pedigree and document progressive motor, cognitive, and psychiatric findings. Huntington disease is an autosomal dominant disorder caused by a CAG-repeat expansion in HTT on chromosome 4; the classic clinical syndrome combines progressive motor dysfunction, cognitive decline, and psychiatric disturbance. [16]

Order targeted HTT CAG-repeat analysis when the clinical phenotype is compatible with Huntington disease, particularly with an affected parent or other convincing family history. A repeat length of 36 or more is described as disease-causing; in a symptomatic person, molecular confirmation resolves diagnostic uncertainty created by variable psychiatric, cognitive, and motor presentation. [16]

Do not equate a positive molecular result with a motor diagnosis in an asymptomatic carrier. Formal clinical diagnosis has traditionally relied on diagnostic motor signs in a person with a positive family history, confirmed by gene testing; a mutation carrier without diagnostic motor signs should be managed as premanifest rather than assigned symptomatic disease solely from genotype. [16]
- Ask specifically about affected relatives on both parental lineages, age at onset, psychiatric hospitalization, unexplained falls, dysphagia, and early cognitive or occupational decline; an apparently negative pedigree does not exclude disease. [16]
- Treat pediatric or adolescent rigidity, bradykinesia, cognitive decline, behavioral change, or seizures in an at-risk family as a possible juvenile presentation; juvenile cases often have more than 55 CAG repeats. [16]
- When the phenotype is chorea-predominant but HTT testing is negative, reopen the differential rather than labeling the patient as gene-negative Huntington disease; clinically diagnosed phenocopies occur. [16]

*HTT CAG-repeat interpretation relevant to diagnostic and family counseling decisions. [16][20]*

| HTT CAG-repeat result | Clinical interpretation | Next decision |
| --- | --- | --- |
| Less than 27 repeats | Reported as normal. [20] | If the phenotype remains progressive chorea with cognitive or psychiatric decline, investigate alternative chorea disorders and Huntington disease phenocopies. [16][20] |
| 27-35 repeats | Intermediate range: does not cause Huntington disease but may expand in subsequent generations. [20] | Provide reproductive and family counseling focused on intergenerational expansion rather than diagnosing the tested person with Huntington disease. [20] |
| 36 or more repeats | Disease-causing HTT expansion; longer repeats are associated with earlier onset. [16] | Integrate with motor examination and functional assessment; initiate symptomatic and multidisciplinary care if clinically manifest. [16] |
| Often more than 55 repeats | Typical association reported for juvenile Huntington disease. [16] | Expedite pediatric neurology, neurogenetics, rehabilitation, and family support planning when juvenile phenotype is suspected. [13][16] |

## Separate Huntington disease from secondary chorea and phenocopies

Negative HTT testing or an atypical course should trigger a structured reassessment.

For a patient with new or subacute chorea, first review medication exposure and evaluate for general internal or iatrogenic causes before attributing the syndrome to Huntington disease. The recognized differential includes general internal disorders, drug-induced chorea, and inherited Huntington disease phenocopies. [16]

A negative HTT result in a patient with a Huntington-like syndrome changes the next action: document the exact motor phenotype, cognitive profile, psychiatric syndrome, and family structure; obtain focused neurogenetic assessment rather than repeating HTT testing without a laboratory reason. Phenocopies are observed among clinically diagnosed cases lacking the HTT mutation. [5][16]

Use CAG repeat length as a prognostic modifier, not a stand-alone forecast for an individual patient. Repeat length correlates with age at onset, but genetic modifiers also influence clinical onset and progression; DNA-maintenance loci have been identified as modifiers in genome-wide studies. [8][10][11][15]
- Reassess an apparently sporadic presentation for an unrecognized affected parent, adoption, early parental death, estrangement, or prior psychiatric misdiagnosis before concluding that the case is nonfamilial. [16]
- Refer an HTT-negative Huntington-like syndrome to neurogenetics when the phenotype remains progressive after secondary and medication causes are addressed; the key discriminator is absence of the causative HTT expansion despite a compatible syndrome. [16]
- Avoid using modifier-gene testing for routine predictive counseling; current counseling is guided by CAG repeat number and family history, and modifier testing remains an area of clinical uncertainty. [15]

*Actionable diagnostic branches in suspected Huntington disease. [16][20]*

| Presentation or result | Most useful discriminator | Clinical next step |
| --- | --- | --- |
| Compatible progressive syndrome with affected parent | HTT CAG-repeat analysis. [16] | Confirm molecular status and stage clinically by diagnostic motor signs and functional consequences. [16] |
| Chorea with recent medication exposure or systemic illness | Medication review and evaluation for general internal or iatrogenic causes. [16] | Address the secondary cause before assigning a hereditary neurodegenerative diagnosis. [16] |
| Huntington-like syndrome with negative HTT result | No pathogenic HTT expansion despite clinical resemblance. [16] | Evaluate for phenocopy and alternative etiologies through neurogenetic assessment. [5][16] |
| At-risk person without diagnostic manifestations | Testing indication is predictive, not diagnostic. [16] | Use a structured multidisciplinary predictive-testing process rather than routine symptom-driven testing workflow. [16][19] |

## Use a protected pathway for predictive and reproductive testing

Predictive testing has consequences for mental health, family systems, insurance, employment, and reproduction.

Offer predictive HTT testing only to an at-risk adult who requests to know carrier status and completes a multidisciplinary pretest process. Predictive testing can identify expanded-repeat carriers before symptom onset, but premanifest diagnosis should be conducted by multidisciplinary teams rather than treated as a simple screening assay. [16]

Before blood draw, establish the patient’s reason for testing, readiness to receive either result, psychiatric history, available support person, planned method of disclosure, and immediate post-result contact plan. Contemporary predictive-testing frameworks emphasize structured pretest counseling and mental-health considerations; family-system implications are particularly relevant for candidates at 25% risk. [17][19]

For reproductive decisions, explain that an intermediate allele of 27-35 repeats does not cause Huntington disease in the carrier but can expand in subsequent generations. Discuss referral to reproductive genetics when an expanded allele or intermediate allele creates concern about transmission; prenatal diagnosis using chorionic villus sampling is described as an available option. [16][20]
- Do not use a diagnostic motor examination to pressure an asymptomatic at-risk person into predictive testing; the decision to know carrier status remains voluntary. [16][19]
- If the patient has active depression, suicidality, psychosis, unstable substance use, or inadequate support, address stabilization and arrange mental-health follow-up before proceeding with predictive disclosure. Structured protocols emphasize mental-health considerations because the result can have major psychosocial consequences. [17][19]
- Provide counseling to relatives separately from the tested person when needed; each relative has an independent decision about whether to learn risk or undergo testing. [17][19]

*Testing indication determines the counseling and follow-up pathway. [16][17][19][20]*

| Testing context | Required clinical framing | Key downstream action |
| --- | --- | --- |
| Symptomatic diagnostic testing | Compatible progressive motor, cognitive, or psychiatric syndrome; interpret with examination and pedigree. [16] | Confirm or redirect the etiologic evaluation and establish symptom-focused longitudinal care. [16] |
| Premanifest predictive testing | At-risk adult electing to learn status; use multidisciplinary counseling and planned result disclosure. [16][19] | Arrange mental-health and family-support follow-up regardless of result. [17][19] |
| Intermediate allele | 27-35 repeats do not cause Huntington disease in the tested person. [20] | Discuss possible expansion in future generations and offer reproductive genetics counseling. [20] |
| Prenatal testing consideration | Potential parental transmission of an HTT expansion. [16] | Refer for reproductive genetics discussion; chorionic villus sampling is a described prenatal diagnostic option. [16] |

## Treat the symptom that is driving injury, distress, or loss of function

No curative therapy is established; treatment targets the manifestations causing the greatest current harm.

Treat chorea when it interferes with activities, causes injury, or materially burdens the patient or caregiver. Up to 90% of affected patients may develop chorea; tetrabenazine is FDA-indicated for Huntington chorea, and deutetrabenazine was FDA-approved for Huntington chorea in 2017. [1][4][24]

Select a vesicular monoamine transporter 2 inhibitor after screening for depression, suicidal thoughts, and suicidal behavior. Tetrabenazine has serious warnings for depression and suicidality; this risk is particularly consequential because psychiatric symptoms can be among the most difficult manifestations of Huntington disease for patients and caregivers. [1]

Deutetrabenazine is a reasonable alternative when twice-daily administration and lower plasma fluctuation are advantageous. In FIRST-HD, deutetrabenazine improved chorea and motor outcomes versus placebo; its deuterated pharmacokinetic profile permits lower peak concentrations and reduced fluctuations than tetrabenazine, although no head-to-head randomized trial has established comparative efficacy between the two agents. [4][23][24]

A patient receiving stable, beneficial tetrabenazine can be converted overnight to deutetrabenazine under an appropriate conversion plan; an open-label study evaluated overnight switching in 37 patients. Use clinical follow-up to reassess chorea benefit, mood, behavior, sleep, and functional impact after conversion rather than assuming pharmacologic equivalence in every patient. [4]
- Use antipsychotics such as haloperidol or risperidone when psychosis, severe behavioral disturbance, or other psychiatric symptoms require treatment; these agents are frequently used symptomatically in Huntington disease. [1]
- Use antidepressants such as citalopram or sertraline for depressive symptoms when clinically indicated, while monitoring for worsening mood or suicidality in the overall psychiatric plan. [1]
- Avoid treating chorea solely because it is visible. The treatment threshold is functional interference, injury risk, patient distress, or caregiver burden; suppressing chorea may not improve every patient’s overall function. [4]
- Reassess psychiatric symptoms at each medication change because worsening disease and medication adverse effects can both alter mood and behavior. [1][6]

### Function, communication, and nutrition

Refer early to physical therapy and occupational therapy to maximize physical function; add speech therapy when communication or swallowing function is affected. These interventions should be linked to a specific deficit—falls and gait instability, impaired transfers, loss of hand function, dysarthria, or dysphagia—rather than ordered generically. [1]

Escalate nutritional support when weight loss, prolonged meals, dysphagia, or inadequate intake develops. Nutritional support, psychological counseling, family counseling, and speech therapy are recognized components of multidisciplinary symptomatic management in progressive disease. [1][6]
- Make caregiver capacity an explicit treatment target: family counseling and psychological support address the cumulative psychiatric, cognitive, and functional demands of disease progression. [1]
- Reassess rehabilitation goals as motor and cognitive decline progress; interventions are directed at preserving function rather than reversing neurodegeneration. [1][6]

*Symptom-targeted treatment choices in Huntington disease. [1][4][23][24]*

| Clinical problem | Treatment option | Selection and monitoring issue |
| --- | --- | --- |
| Function-limiting or injurious chorea | Tetrabenazine, FDA-indicated for Huntington chorea. [1] | Screen and monitor for depression, suicidal thoughts, and suicidal actions. [1] |
| Function-limiting or injurious chorea | Deutetrabenazine, FDA-approved for Huntington chorea. [4][24] | Twice-daily dosing and reduced plasma fluctuations may be advantageous; randomized head-to-head comparative efficacy data versus tetrabenazine are lacking. [4][24] |
| Psychosis or severe behavioral symptoms | Haloperidol or risperidone are frequently used symptomatically. [1] | Choose based on the target psychiatric syndrome and monitor clinical response and adverse effects. [1] |
| Depressive symptoms | Citalopram or sertraline are frequently used symptomatically. [1] | Monitor mood and suicidality, especially when initiating or changing therapy. [1] |
| Mobility, activities of daily living, speech, or swallowing impairment | Physical therapy, occupational therapy, speech therapy, and nutritional support. [1] | Tie referral to measurable functional deficits and reassess as disease progresses. [1][6] |

## Organize longitudinal care around function, safety, and trial readiness

Progression requires anticipatory reassessment rather than a one-time movement-disorder treatment plan.

At follow-up, reassess motor function, cognition, psychiatric symptoms, weight and intake, speech and swallowing, falls, caregiver burden, and practical supports. Huntington disease remains progressive despite available symptomatic therapies, and current treatments reduce symptom impact without adequately controlling worsening across disease progression. [1][6]

Use a multidisciplinary clinic model when available because motor, psychiatric, cognitive, nutritional, communication, and family needs commonly coexist. For juvenile Huntington disease, multidisciplinary symptomatic and supportive management is particularly emphasized because developmental, educational, and caregiver decisions accompany progressive neurologic disease. [1][13]

Discuss clinical-trial referral with interested patients and families, particularly at specialized Huntington disease centers. Targeted huntingtin-lowering approaches and biomarkers have been major areas of therapeutic development, but they should be presented as investigational rather than disease-modifying standard care. [3][6][7]

Do not offer modifier-gene testing or experimental huntingtin-lowering therapy as routine clinical management. Genetic studies indicate that pathogenesis may be modifiable before clinical diagnosis and that modifier loci act early, but this does not establish a current individual-level treatment indication. [10][11][15]
- Document the specific consequence of each dominant symptom—fall, injury, work failure, medication nonadherence, aspiration concern, weight loss, psychosis, depression, or caregiver exhaustion—to prioritize the next intervention. [1][6]
- Revisit advance care planning and decision-making support as cognitive and functional decline begin to impair independent management of health, finances, or safety. Progressive cognitive and motor dysfunction are core manifestations of Huntington disease. [16]
- Provide relatives with separate access to genetics, mental-health, and family counseling resources; disease burden extends beyond the identified patient. [1][17][19]

*Longitudinal reassessment domains and action triggers in Huntington disease. [1][6][13][16]*

| Domain | Action trigger | Next intervention |
| --- | --- | --- |
| Chorea and falls | Chorea interferes with daily function or causes injury. [4] | Reassess need for VMAT2 inhibition and physical or occupational therapy. [1][4] |
| Mood and behavior | Depression, suicidal thoughts, psychosis, or escalating behavioral symptoms. [1] | Urgently assess safety; adjust psychiatric treatment and involve mental-health support. [1][19] |
| Speech, swallowing, and intake | Dysarthria, dysphagia, prolonged meals, or inadequate nutrition. [1] | Refer to speech therapy and nutritional support. [1] |
| Juvenile disease | Early-onset neurobehavioral, cognitive, or motor decline in an at-risk family. [13][16] | Coordinate pediatric neurology, neurogenetics, school planning, rehabilitation, and family support. [13] |
| Interest in disease-modifying therapy | Patient seeks access beyond symptomatic treatment. [3][6] | Discuss referral to an experienced Huntington disease center for investigational-trial consideration. [3][6] |

## References
1. Huntington's Disease — www.fda.gov — https://www.fda.gov/media/96350/download
2. 10/15/2021 Name: Merit Ester Cudkowicz Office Address — www.fda.gov — https://www.fda.gov/media/154850/download
3. Christopher S. Coffey — www.fda.gov — https://www.fda.gov/media/179801/download
4. Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea — jamanetwork.com — https://jamanetwork.com/journals/jamaneurology/fullarticle/2643174
5. Huntington Disease — jamanetwork.com — https://jamanetwork.com/collections/42085/huntington-disease
6. Huntington disease | Nature Reviews Disease Primers — www.nature.com — https://www.nature.com/articles/nrdp20155.pdf
7. Huntington disease: natural history, biomarkers and prospects for therapeutics | Nature Reviews Neurology — www.nature.com — https://www.nature.com/articles/nrneurol.2014.24/boxes/bx2
8. Genetic modifiers of Huntington disease differentially ... — www.cell.com — https://www.cell.com/ajhg/fulltext/S0002-9297(22)00100-8
9. Long somatic DNA-repeat expansion drives ... — www.cell.com — https://www.cell.com/cell/fulltext/S0092-8674%2824%2901379-5
10. Identification of Genetic Factors that Modify Clinical Onset ... — www.cell.com — https://www.cell.com/cms/10.1016/j.cell.2015.07.003/attachment/84754442-1e6b-475d-b7b9-42d725d544a2/mmc5.pdf
11. Genetic Modification of Huntington Disease Acts Early in ... — www.cell.com — https://www.cell.com/ajhg/fulltext/S0002-9297(18)30244-1
12. Systematic Review of Quality Dementia Clinical Guidelines for ... — academic.oup.com — https://academic.oup.com/gerontologist/article/63/9/1536/6679398
13. 4 Juvenile Huntington's Disease - Oxford Academic — academic.oup.com — https://academic.oup.com/book/25254/chapter/189793029
14. Preventing amyotrophic lateral sclerosis: insights from pre ... — academic.oup.com — https://academic.oup.com/brain/article/145/1/27/6408437
15. Genetic Testing of HTT Modifiers for Huntington's Disease ... — movementdisorders.onlinelibrary.wiley.com — https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.29650
16. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S147444220970170X
17. Predictive Genetic Testing: The Huntington Disease Model — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/abs/10.1002/9780470015902.a0005617.pub2
18. Diagnosis of Huntington's Disease - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/diagnosis-of-huntingtons-disease
19. 40+ years of the Huntington disease predictive genetic ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/jgc4.70226
20. Huntington Disease Like Syndrome - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/huntington-disease-like-syndrome
21. Technical Standards and Guidelines for Huntington Disease Testing — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S109836002103803X
22. Medication Use and Treatment Indications in Huntington's ... — movementdisorders.onlinelibrary.wiley.com — https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mdc3.14230
23. Pharmacokinetics of Deutetrabenazine and Tetrabenazine ... — accp1.onlinelibrary.wiley.com — https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/cpdd.882
24. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington’s disease - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818866

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.